ESMO 2019 | Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts
Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Hope Rugo, MD, FASCO, UCSF Comprehensive Cancer Center, San Diego, CA, discusses the SOLAR-1 trial (NCT02437318). This trial is investigating alpelisib with fulvestrant for the treatment of HR+/HER2- advanced breast cancer. Here, Dr Rugo discusses the management and time course of key adverse events of special interest.
Get great new content delivered to your inboxSign up